ClinicalTrials.gg
RecruitingNCT04752774LANTIMAUpdated Jul 28, 2026

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

A Phase 1/2 interventional study of Corabotase and Placebo in Spasticity, sponsored by Ipsen. Recruiting at 81 sites in 14 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Ipsen · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Muscle Spasticity by Ipsen — 1 open to participants now, 1 under way, none of them phase 3. Muscle Spasticity · Ipsen.

Started
2021
with 2 others
Phase 1/2
Only one
of the 15
Registered
14th of 15
by date

Among the 15 studies in Muscle Spasticity by Ipsen, this one is one of 3 that started in 2021, is the only one in phase 1/2, and was the 14th registered.

Muscle Spasticity

626 studies on the registry are indexed under Muscle Spasticity; 131 are open to participants now.

Browse Muscle Spasticity studies →

Open to participants now

1 of the 15 studies in Muscle Spasticity by Ipsen is open now, in 12 countries.

By country, each count listing its studies:

Who these studies take

Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Muscle Spasticity by Ipsen, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety and efficacy of increasing doses of Corabotase (also known as IPN10200) with the aim to evaluate the Pharmacodynamics (PD) profile of Corabotase and to establish the total Corabotase doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.

03

Conditions studied

  • Spasticity

Keywords

  • Upper limb spasticity after stroke or traumatic brain injury
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 18 to 70 years of age inclusive (except for dose escalation must be 18 to 65 years of age) at the time of signing the .
  2. Has spastic hemiparesis following stroke or Traumatic brain injury (TBI)
  3. Is at least 6 months post-stroke or TBI
  4. Has never received BoNT or if previously treated, should have received their last injection of any commercialized BoNT-A or B at least 4 months prior to study Baseline
  5. Has a MAS score ≥2 in the (PTMG) to be injected
  6. Is eligible to receive a total recommended dose 1000 U Dysport in the upper limb when applicable.
  7. Has angle of spasticity ≥5° in the PTMG to be injected.
  8. Does not have any fixed contractures as defined by:

    • Complete fingers extension with Angle of arrest at slow speed (Tardieu Scale) (XV1) ≥160°
    • Complete wrist extension with XV1 ≥90°
    • Complete elbow extension with XV1 ≥160°
  9. Physiotherapy, occupational therapy, splinting, use of benzodiazepine, and muscle relaxants had to be stable from at least 30 days preceding the study Baseline up to the Month 3 visit, and whenever possible until the end of the study.
  10. In good health (i.e. absence of any uncontrolled systemic disease or other significant medical condition) as determined by medical history, physical and neurological examinations, clinical laboratory studies, (ECGs), vital signs, and Investigator's judgment prior to randomization
  11. Male and female participants use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Male participants must agree that, if their partner is at risk of becoming pregnant, they will use an effective method of contraception. The participants must agree to use the contraception during the whole period of the study.

A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non- (WONCBP) or is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method (until the end of the study). The investigator should evaluate the potential for contraceptive method failure in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive pregnancy test.

Exclusion criteria

Exclusion Criteria:

  1. Any medical condition (including severe dysphagia or airway disease) that may increase, in the opinion of the investigator, the likelihood of adverse events (AEs) related to BoNT treatment.
  2. Known disease of the neuromuscular junction (e.g. Lambert-Eaton myasthenic syndrome, myasthenia gravis or amyotrophic lateral sclerosis etc.).
  3. Has a history of to the medicinal products (or other BoNTs) or any used in their formulation.
  4. Clinically diagnosed significant anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the participant's participation in the study.
  5. Likely treatment with any serotype of BoNT for any condition during the study.
  6. Undergone previous surgery to treat spasticity in the affected upper limb.
  7. Has initiated physiotherapy within 30 days prior to Baseline (if physiotherapy initiated more than 30 days prior to Baseline and ongoing, the therapy regimen should be maintained at the same frequency and intensity throughout the study if possible or at least up to 3-months post-injection).
  8. Has received previous treatment with phenol and or alcohol in the targeted upper limb any time before the study.
  9. Has been treated or is likely to be treated with intrathecal baclofen during the 30 days prior to study Baseline or during the course of the study.
  10. Current or planned treatment with any medications that interfere either directly or indirectly with neuromuscular transmission, such as curare-like non depolarising agents, lincosamides, polymyxins, anticholinesterases and aminoglycoside antibiotics, within 30 days prior to Baseline.
  11. Use of concomitant therapy which, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study intervention, including medications affecting bleeding disorders. For patients taking vitamin K antagonists, the values should be controlled (between 2 and 3)
  12. Currently planned or a history of tendon lengthening surgery, significant contracture or muscle atrophy at target joint or muscle in the past 6 months prior to Screening.
  13. Use of any experimental device within 30 days or use of any treatment with an experimental drug within five times the documented terminal half-life of the respective drug or its metabolites or if the half-life is unknown within 30 days prior to the start of the study (prior to Baseline) and during the conduct of the study.
  14. Presence of any other condition (e.g. neuromuscular disorder, muscular dystrophies, cancer cachexia, sarcopenia or other disorder that could interfere with neuromuscular function), laboratory finding or circumstance that, in the judgment of the investigator, might increase the risk to the participant or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
  15. Pregnant or lactating women, or women of not willing to practice a highly effective form of method at the beginning of the study, for the duration of the study and for the duration of the study
  16. Inability to understand protocol procedures and requirements
  17. Infection at the injection site(s)
  18. A history of drug or alcohol abuse
  19. Male participants who are not vasectomised and who have female partners of childbearing potential and are not willing to use condoms with spermicide throughout study participation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Dose escalation

    One single administration of study medication (Corabotase, Dysport or placebo) will be injected in a dose-escalation manner. Dose-escalation will include several cohorts.

    Biological: Corabotase · Drug: Placebo · Biological: Dysport

  • Experimental
    Dose ranging

    Two fixed doses of Corabotase will be administrated as a single injection into several muscle groups of the upper limb. Participants will be randomised in the ratio of 3:3:2 (total Corabotase dose 1: 30 participants; total Corabotase dose 2: 30 participants; Dysport: 20 participants)

    Biological: Corabotase · Biological: Dysport

  • Experimental
    Total dose

    One single injection of study medication will be administered locally into several muscle groups of the upper limb. Participants will be randomized in the ratio of 2:1 (Total Corabotase dose: 30 participants; placebo: 15 participants, resulting in a total of 45 participants in Stage 3). Or Participants will be randomized in the ratio of 3:1 (Corabotase lower dose: 30 participants; placebo: 10 participants, then Corabotase higher dose: 30 participants; placebo: 10 participants, resulting in a total of 80 participants in Stage 3).

    Biological: Corabotase · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants with treatment emergent adverse events (TEAEs).

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From baseline until the end of study (9 months)

  2. Percentage of participants with adverse events of special interest (AESI).

    Time frame: From baseline until the end of study (9 months)

  3. Change from baseline in vital sign parameter (blood pressure)

    Time frame: 9 months

  4. Change from baseline in vital sign parameter (Heart rate)

    Time frame: 9 months

  5. Change from baseline in clinical laboratory test results.

    Number and percentage of participants with low, normal or high values and normal or abnormal examinations will be presented.

    Time frame: 9 months

  6. Presence of IPN10200 and BoNT-A antibodies (binding and neutralising)

    Time frame: From baseline until the end of study (9 months)

  7. Change from baseline in physical examination findings.

    Number of Participants with change in physical examination findings

    Time frame: 9 months

Secondary outcomes

  1. Change from Baseline to all post-treatment visits in Modified Ashworth scale (MAS) score in the Primary target muscle group (PTMG)

    MAS is a scale to assess muscle tone in the injected muscles. The muscle tone will be rated as per grading from 0 to 4, there 0 =No increase in muscle tone and 4 =Affected part(s) rigid in flexion or extension.

    Time frame: from baseline until the end of study (9 months)

  2. Change from Baseline to post-treatment Day 29 in MAS score in the PTMG.

    If PD profile of IPN10200 in dose escalation indicates a peak of effect different than Day 29, the endpoint will be modified accordingly)

    Time frame: From baseline until post-treatment Day 29

  3. Change from Baseline in MAS score in all injected muscle Groups

    Time frame: From baseline until the end of study (9 months)

  4. Time to onset - time to the response to treatment (a reduction of at least one grade in the MAS score).

    Time frame: From baseline until the end of study (9 months)

  5. Peak of effect - maximal decrease in the MAS score from Baseline.

    Time frame: From baseline until the end of study (9 months)

  6. Time to peak - time to reach the peak of effect (maximal decrease in the MAS score from Baseline).

    Time frame: From baseline until the end of study (9 months)

  7. Duration of effect - duration between time to onset and last timepoint with a response to Treatment.

    Time frame: From baseline until the end of study (9 months)

  8. Response to treatment as measured by at least one grade reduction in MAS score in the PTMG from Baseline

    Time frame: From baseline until the end of study (9 months)

  9. Response to treatment as measured by at least one grade reduction in MAS score in all injected muscles from Baseline

    Time frame: From baseline until the end of study (9 months)

  10. Physician's Global Assessment (PGA) score of overall treatment response

    The PGA is a 9-point scale (from -4= markedly worse to +4=markedly improved) used to assess global overall treatment response by the investigator.

    Time frame: From baseline until the end of study (9 months)

  11. Patient Global Impression of Change in the Spastic Clinical Pattern using specific scale (PGI-c)

    PGI-C is a scale to assess global impression of change in the spastic clinical pattern using a 7-point Likert scale (from -3: very much worse to +3: very much improved) by answering a specific question

    Time frame: from baseline until the end of study (9 months)

  12. Change from Baseline in the Disability Assessment Scale (DAS)

    The DAS will be used to assess the effect of upper limb spasticity on hygiene, dressing, limb position and pain. Participants will be assessed in an interview format.

    Time frame: From baseline until the end of study (9 months)

  13. Reduction of pain in the shoulder (adducted/rotated pattern) using the Numeric Rating Scale

    Time frame: From baseline until the end of study (9 months)

  14. The number and percentage of participants with presence of IPN10200 and BoNT-A antibodies and titres (binding and neutralising)

    Time frame: At baseline

07

Study locations

54 of 81 sites recruiting
  • Rancho Los Amigos National Rehab
    Downey, California 90242, United States
    Recruiting
  • Kansas Institute of Research
    Overland Park, Kansas 66211, United States
    Recruiting
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Einstein Physical Medicine and Rehabilitation at Elkins Park
    Elkins Park, Pennsylvania 19027, United States
    Recruiting
  • The University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
    Recruiting
  • Medical University Innsbruck, Department of Neurology
    Innsbruck, 6020, Austria
    Recruiting
  • Kepler University Hospital GmbH, Department of Neurology and Psychiatry
    Linz, 4021, Austria
    Recruiting
  • Brothers of Charity Hospital Linz, Department of Neurology I
    Linz, A-4021, Austria
    Recruiting
  • Medical University Vienna, Department of Neurology
    Vienna, 1090, Austria
    Withdrawn

    Not enrolling at this site — choose another above.

  • Multiprofile Hospital for Active Treatment "Heart and Brain"
    Pleven, 5800, Bulgaria
    Withdrawn

    Not enrolling at this site — choose another above.

  • Medical Center "Rusemed" EOOD
    Rousse, 7005, Bulgaria
    Recruiting
  • Multiprofile Hospital for Active Treatment of Neurology and Psychiatry "Sveti Naum", Sofia, Neurological Diseases Clinic for Neurodegenerative and Peripheral Neurological Diseases
    Sofia, 1113, Bulgaria
    Recruiting
  • Diagnostic Consulting Center - Convex EOOD
    Sofia, 1680, Bulgaria
    Recruiting
  • Medical Center Medica Plus Ltd
    Veliko Tarnovo, 5006, Bulgaria
    Recruiting
  • University Hospital Hradec Kralove, Clinic of Neurology
    Hradec Králové, 500 05, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Jihlava, Department of Neurology
    Jihlava, 586 33, Czechia
    Recruiting
  • University Hospital Ostrava, Clinic of Neurology, Center for Demyelinating diseases
    Ostrava, 708 52, Czechia
    Recruiting
  • Regional Hospital Pardubice, Clinic of Neurology
    Pardubice, 532 03, Czechia
    Recruiting
  • University Hospital Kralovske Vinohrady, Clinic of Neurology
    Prague, 100 34, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • General University Hospital in Prague, Clinic of Neurology
    Prague, 120 00, Czechia
    Recruiting
  • Bastia Hospital Center
    Bastia, 20600, France
    Not yet recruiting
  • Bordeaux University Hospital Center - Pellegrin Hospital Group
    Bordeaux, 33076, France
    Not yet recruiting
  • Brest University Hospital Center - Morvan Hospital
    Brest, 29200, France
    Not yet recruiting
  • Raymond-Poincare Hospital - APHP
    Garches, 92380, France
    Not yet recruiting
  • University Hospital Bonn, Clinic and Policlinic for Neurology
    Bonn, 53127, Germany
    Recruiting
  • Heinrich Heine University Medical Center, Department of Neurology
    Düsseldorf, 40225, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • University Medicine Goettingen, Department of Neurology
    Goettigen, 37075, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • University Hospital Hamburg-Eppendorf, Clinic and Polyclinic of Neurology
    Hamburg, 20246, Germany
    Recruiting
  • University Hospital Johannes Gutenberg - University of Mainz, Clinic and Polyclinic of Neurology
    Mainz, 55131, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Ludwig Maximilians University Hospital, Campus Grosshadern, Department of Neurology
    Munich, 81377, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • GFO Clinics Troisdorf, St. Johannes Sieglar
    Troisdorf, 53844, Germany
    Recruiting
  • University Hospital Tuebingen, Department of Neurology
    Tübingen, 72076, Germany
    Recruiting
  • Semmelweis University, Rehabilitation Clinic, Rehabilitation Department of Brain Injuries
    Budapest, Hungary
    Recruiting
  • University of Debrecen Clinical Center, Department of Medical Rehabilitation and Physical Medicine
    Debrecen, H-4031, Hungary
    Recruiting
  • Petz Aladar University Teaching Hospital, Department of Neurology
    Győr, Hungary
    Recruiting
  • Szent Damjan Greek Catholic Hospital, Department of Neurology and Stroke
    Kisvárda, H-4600, Hungary
    Recruiting
  • Borsod-Abauj-Zemplen County Central Hospital and University Educational Hospital, Department of Neurology
    Miskolc, Hungary
    Recruiting
  • ASST Spedali Civili Brescia
    Brescia, 25123, Italy
    Recruiting
  • University Hospital "Federico II"
    Naples, 80131, Italy
    Not yet recruiting
  • University Polyclinic Foundation "Agostino Gemelli" - IRCCS
    Rome, 00168, Italy
    Not yet recruiting
  • Clinical Research Center of Verona S.r.l. - CRC
    Verona, 37134, Italy
    Recruiting
  • Fukuoka Rehabilitation Hospital
    Fukuoka, Japan
    Recruiting
  • Chutoen General Medical Center, Department of Rehabilitation
    Shizuoka, Japan
    Recruiting
  • Tokushima University Hospital
    Tokushima, 770-8503, Japan
    Recruiting
  • NHO Murayama Medical Center, Department of Rehabilitation
    Tokyo, Japan
    Recruiting
  • St Wojciech - Adalbertus Hospital, Neurology Department
    Gdansk, 80-462, Poland
    Recruiting
  • Specialist Doctor Practice
    Katowice, 40-097, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Ma-Lek MS Therapy Centre
    Katowice, 40-571, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Neuro-Medic
    Katowice, 40-686, Poland
    Recruiting
  • Specialist Practises LLC
    Krakow, 30-539, Poland
    Recruiting
  • Linden Medical Center
    Krakow, 30-721, Poland
    Recruiting
    • Specialist P LLC · Contact
  • Clinical Center for Neurology Sp. z o .o. (LLC)
    Krakow, 31-505, Poland
    Recruiting
    • Specialist P LLC · Contact
  • NeuroKlinika - Private Practice Prof. Andrzej Bogucki
    Lodz, 90-640, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Health Institute Dr n. med. Magdalena Boczarska-Jedynak
    Oświęcim, 32-600, Poland
    Recruiting
  • Clinical Research Center SP. ZOO MEDIC-R
    Poznan, 61-731, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Neuro-Kard Ilkowski and Partners
    Poznan, 61-853, Poland
    Recruiting
  • Holy Spirit Specialist Hospital in Sandomierz - Neurology Teaching Hospital, Neurology Department
    Sandomierz, 27-600, Poland
    Recruiting
  • Wolski Hospital, Neurological Department
    Warsaw, 01-211, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • NeuroProtect Medical Center
    Warsaw, 01-684, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • EuroMediCare Specialist Outpatient Clinics in Wroclaw
    Wroclaw, 50-220, Poland
    Recruiting
  • Alto Ave Central Hospital
    Guimarães, 4835-044, Portugal
    Recruiting
  • Local Health Unit Loures-Odivelas E.P.E.
    Loures, 2674-514, Portugal
    Recruiting
  • Local Health Unit of Matosinhos (ULSM), EPE - Pedro Hispano Hospital
    Matosinhos Municipality, 4464-513, Portugal
    Recruiting
  • Local Unit of Health in Alto Minho, EPE
    Viana do Castelo, 4904-858, Portugal
    Recruiting
  • Federal Siberian Research and Clinical Center, Department of Nervous Diseases, Traditional Medicine with Course in Postgraduate Education
    Krasnoyarsk, 660049, Russia
    Withdrawn

    Not enrolling at this site — choose another above.

  • National Medical Research Center Treatment and Rehabilitation Center, Department of Neurology
    Moscow, 125367, Russia
    Withdrawn

    Not enrolling at this site — choose another above.

  • "Praximed" - Diagnostic and Rehabilitation Center, Rehalibitation Department
    Saint Petersburg, 194223, Russia
    Withdrawn

    Not enrolling at this site — choose another above.

  • N.P. Bekhtereva Research Institute of Human Brain
    Saint Petersburg, 197376, Russia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Astarta, LLC, Department of Neurology
    Saint Petersburg, 199226, Russia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Medical and Sanitary Unit #70 of "Passazhiravtotrans"
    Saint Petersburg, Russia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Dongguk University Ilsan Hospital
    Goyang-si, 10326, South Korea
    Recruiting
  • The Catholic University of Korea - Incheon St. Mary's Hospital
    Incheon, 21431, South Korea
    Recruiting
  • Seoul National University Bundang Hospital
    Seongnam-si, 13620, South Korea
    Recruiting
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
    Recruiting
  • Hospital Maritimo de Oza
    A Coruña, 15006, Spain
    Recruiting
  • University Hospital Vall d'Hebron
    Barcelona, 08035, Spain
    Recruiting
  • Juan Ramon Jimenez Hospital
    Huelva, 21005, Spain
    Recruiting
  • University Hospital de La Princesa, Physical Medicine and Rehabilitation
    Madrid, 28006, Spain
    Recruiting
  • Santiago de Compostela Clinical Hospital, Physical Medicine and Rehabilitation
    Santiago de Compostela, 15706, Spain
    Recruiting
  • University Hospital Virgen Macarena, Physical Medicine and Rehabilitation
    Seville, 41009, Spain
    Recruiting
  • Meixoeiro Hospital at Vigo University Hospital Complex
    Vigo, 36200, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2021 (actual). Primary completion is estimated for Mar 2029, 95 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2021
First posted
Feb 12, 2021
StartActual
Apr 29, 2021
Primary completionEst.
Mar 30, 2029
CompletionEst.
Mar 30, 2029
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04752774
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Feb 12, 2021
Start date
Apr 29, 2021
Primary completion
Mar 30, 2029 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Jul 28, 2026

Study contacts

Ipsen Recruitment Enquiries
Contact
clinical.trials@ipsen.com
see email
Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion